PTK2 and glioblastoma: Functional and on-target validation of the MEK and FAK inhibitors used in this GBM cell model was carried out, with reduced phosphorylated (p)-FAK and phosphorylated (p)-ERK, as observed by Western blotting (Figure 2F).